302440 — SK Bioscience Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapSucker Stock

Annual cashflow statement for SK Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	32,890	355,139	122,452	22,318	-50,117
Depreciation
Amortisation
Non-Cash Items	8,612	130,619	36,221	7,969	-166,631
Unusual Items
Other Non-Cash Items
Changes in Working Capital	62,195	32,060	-310,868	-35,705	39,503
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	120,224	536,594	-124,958	29,346	-128,020
Capital Expenditures	-10,198	-44,470	-76,489	-50,295	-172,225
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-97,895	-1,377,471	349,136	5,017	225,789
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-108,093	-1,421,940	272,647	-45,279	53,564
Financing Cash Flow Items	-301	-628	—	5,484	-4,467
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-1,539	958,380	-19,867	-89,583	252,479
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	10,592	73,056	127,259	-98,262	185,676